Managing chronic neuropathic pain often requires opioid medications, which can carry risks related to dependence and misuse. In this preclinical study, researchers examined whether cannabidiol (CBD) could influence opioid use while preserving pain relief. Using a rat model of neuropathic pain, scientists allowed animals to self-administer the opioid oxycodone, enabling researchers to measure how CBD affected opioid-seeking behavior alongside analgesic outcomes. (pmc.ncbi.nlm.nih.gov)

The results showed that CBD significantly reduced oxycodone self-administration, suggesting it may decrease the reinforcing or rewarding effects associated with opioid use. Importantly, CBD did not interfere with oxycodone’s pain-relieving properties. Rats receiving CBD continued to experience analgesic benefits while taking lower amounts of the opioid. Researchers also observed that CBD influenced biological pathways involved in stress, reward signaling, and pain processing, which may help explain its dual effects on both pain management and opioid intake. (pmc.ncbi.nlm.nih.gov)

Although these findings come from an animal model rather than human clinical trials, the study provides early evidence that CBD may serve as a supportive strategy alongside conventional pain treatments, potentially helping reduce opioid consumption while maintaining effective pain control. The authors emphasize that further human research is needed to confirm safety, dosing, and real-world clinical applications. (pmc.ncbi.nlm.nih.gov)

Source

Bruijnzeel AW, et al. Cannabidiol reduces oxycodone self‑administration while preserving its analgesic efficacy in a rat model of neuropathic pain (January 2026) Available through the National Library of Medicine (NIH): https://pmc.ncbi.nlm.nih.gov/articles/PMC12808320/